Early results in a phase 2 trial are finding that adding a TNF blocker to other treatment could greatly lower the risk of serious complications during pregnancy for women who have antiphospholipid syndrome with lupus anticoagulant.
Advocating for Change: Q&A with Georgia State Rep. Kim Schofield
Rep. Kim Schofield’s path to the Georgia House of Representatives started with her lupus diagnosis 20 years ago.
Baby on Board: The Rheumatologist’s Role in Family Planning for Patients with Lupus
For patients with lupus, family planning discussions are vital to achieving positive pregnancy outcomes & maintaining overall health…
Atmospheric & Environmental Changes Tied to Organ-Specific Lupus Flares
NEW YORK (Reuters Health)—Changes in atmospheric and environmental factors may contribute to organ-specific disease exacerbation in patients with systemic lupus erythematosus (SLE), according to a new study. The study found “strong associations between atmospheric variables and fine particulate matter concentration over the 10 days prior to a patient visit and organ-specific lupus flares at the…
Lupus Flares Pose Greatest Risk for Adverse Pregnancy Outcomes in Women with SLE
According to new research, women with SLE are at the highest risk for adverse pregnancy outcomes during a lupus flare. The data may enable clinicians to use risk stratification and tailored monitoring to counsel SLE patients who are pregnant or considering pregnancy. Researchers also found that maternal age, lupus nephritis and antiphospholipid antibodies may affect pregnancy outcomes…
Lupus Treatments: Into the Future
As the 21st century unfolds, rheumatologists will most likely transition from prescribing lupus patients broad immunosuppressants to more targeted treatment approaches. But to make this happen and advance research, the challenges experienced in lupus clinical trial design must be addressed…
Low-Density Granulocytes Activate T Cells in SLE
Recent research indicates that low-density neutrophils, such as low-density granulocytes, exert proinflammatory effects on the T cells of SLE patients. In the study, researchers confirmed SLE patients had a higher prevalence of low-density granulocytes than healthy controls and that these cells appeared to promote a Th1 response…
Insight into Clinical Trials for Lupus
Research into lupus treatments suffered a setback after the failure of anifrolumab in clinical trials. However, during the 2019 ACR State-of-the-Art Clinical Symposium, Richard Furie, MD, outlined the possibilities of multiple new lupus therapies under investigation…
Ustekinumab May Be Effective for Lupus
New research underscores the possibility that interleukin (IL) 12, IL-23 or both play roles in the immunopathology of SLE. In the study, when added to standard-of-care treatment for active SLE, ustekinumab demonstrated better efficacy than placebo and had a safety profile consistent with that of ustekinumab therapy in other diseases…
AstraZeneca Lupus Drug Fails to Meet Main Goal in Study
(Reuters)—AstraZeneca’s experimental drug anifrolumab failed to meet its main target in a late-stage clinical study treating patients with moderate to severe lupus, the British drugmaker said on Friday. AstraZeneca said the drug did not meet the main goal in the final-stage of one of the two clinical trials under the TULIP program, failing to show…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 18
- Next Page »